title: Rituximab induces different but overlapping sets of genes in human B-lymphoma cell lines.
authors.affiliation: Laboratory of Molecular Immunohaematology, Department of Immunology, Istituto Ricerche Farmacologiche Mario Negri, Milan, Italy.
authors.forename: Elena
authors.initials: E
authors.lastname: Cittera
authors.forename: Chiara
authors.initials: C
authors.lastname: Onofri
authors.forename: Maria
authors.initials: M
authors.lastname: D'Apolito
authors.forename: Guillaume
authors.initials: G
authors.lastname: Cartron
authors.forename: Giovanni
authors.initials: G
authors.lastname: Cazzaniga
authors.forename: Leopoldo
authors.initials: L
authors.lastname: Zelante
authors.forename: Paolo
authors.initials: P
authors.lastname: Paolucci
authors.forename: Andrea
authors.initials: A
authors.lastname: Biondi
authors.forename: Martino
authors.initials: M
authors.lastname: Introna
authors.forename: Josée
authors.initials: J
authors.lastname: Golay
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000096:biosynthesis; D000970:Antineoplastic Agents / Q000494:pharmacology; D017209:Apoptosis; D002448:Cell Adhesion; D045744:Cell Line, Tumor; D017931:DNA Primers / Q000737:chemistry; D018076:DNA, Complementary / Q000378:metabolism; D000077561:Daclizumab; D004305:Dose-Response Relationship, Drug; D004306:Dose-Response Relationship, Immunologic; D004791:Enzyme Inhibitors / Q000494:pharmacology; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007074:Immunoglobulin G / Q000494:pharmacology; D020287:In Situ Nick-End Labeling; D008223:Lymphoma / Q000473:pathology; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000473:pathology; D048369:MAP Kinase Kinase 1 / Q000378:metabolism; D048370:MAP Kinase Kinase 2 / Q000378:metabolism; D020411:Oligonucleotide Array Sequence Analysis; D009841:Oligonucleotides / Q000737:chemistry; D016133:Polymerase Chain Reaction; D012313:RNA / Q000378:metabolism; D018075:RNA, Complementary / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D000069283:Rituximab; D013936:Thymidine / Q000378:metabolism / Q000494:pharmacology; D013997:Time Factors; D018808:Transcription Factor AP-1 / Q000096:biosynthesis; D015533:Transcriptional Activation; D015854:Up-Regulation
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D017931:DNA Primers; D018076:DNA, Complementary; D004791:Enzyme Inhibitors; D007074:Immunoglobulin G; D009841:Oligonucleotides; D018075:RNA, Complementary; D018808:Transcription Factor AP-1; D000069283:Rituximab; D012313:RNA; D000077561:Daclizumab; C482128:MAP2K2 protein, human; D048369:MAP Kinase Kinase 1; D048370:MAP Kinase Kinase 2; D013936:Thymidine